• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society

    10/7/24 8:00:00 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRQR alert in real time by email

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will present preclinical data for its proprietary Axiomer™ RNA editing technology platform and its AX-0810 pipeline program for cholestatic diseases targeting NTCP at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society, October 6-9, 2024, in Montreal, QC, Canada.

    Gerard Platenburg, co-founder and Chief Scientific Officer at ProQR, will present on Tuesday, October 8 at 10:15 am ET (Session IV: DNA/RNA Editing).

    Oral presentation:

    "Oligonucleotide guided RNA editing of SLC10A1 (NTCP) as a therapeutic approach to lower bile acid re-uptake in cholestatic diseases"

    Following OTS, the slide deck will be available via ProQR's website in the Presentations and Publications section.

    About Axiomer™

    ProQR is pioneering a next-generation RNA base editing technology called Axiomer™, which could potentially yield a new class of medicines for diverse types of diseases. Axiomer "Editing Oligonucleotides", or EONs, mediate single nucleotide changes to RNA in a highly specific and targeted way using molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer EONs are designed to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an Inosine (I) in the RNA – an Inosine is translated as a Guanosine (G) – correcting an RNA with a disease-causing mutation back to a normal (wild type) RNA, modulating protein expression, or altering a protein so that it will have a new function that helps prevent or treat disease.

    About ProQR

    ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer™, which uses a cell's own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.

    Learn more about ProQR at www.proqr.com.

    Forward Looking Statements for ProQR

    This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "continue," "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding our presentation at this conference, our Axiomer™ technology, including the continued development and advancement of our Axiomer platform, the therapeutic potential of our Axiomer RNA editing oligonucleotides and our ability to expand preclinical in vivo and in vitro data, the timing, progress and results of our preclinical studies and other development activities, including the release of data related thereto, and the potential of our technologies and product candidates. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our most recent annual report filed on Form 20-F. These risks and uncertainties include, among others, the cost, timing and results of preclinical studies and clinical trials and other development activities by us and our collaborative partners whose operations and activities may be slowed or halted shortage and pressure on supply and logistics on the global market; the likelihood of our preclinical and clinical programs being initiated and executed on timelines provided and reliance on our contract research organizations and predictability of timely enrollment of subjects and patients to advance our clinical trials and maintain their own operations; our reliance on contract manufacturers or suppliers to supply materials for research and development and the risk of supply interruption or delays from suppliers or contract manufacturers; the potential for future data to alter initial and preliminary results of early-stage clinical trials; the unpredictability of the duration and results of the regulatory review of applications or clearances that are necessary to initiate and continue to advance and progress our clinical programs; the ability to secure, maintain and realize the intended benefits of collaborations with partners, including the collaboration with Eli Lilly and Company; the possible impairment of, inability to obtain, and costs to obtain intellectual property rights; possible safety or efficacy concerns that could emerge as new data are generated in research and development; general business, operational, financial and accounting risks, and risks related to litigation and disputes with third parties; and risks related to macroeconomic conditions and market volatility resulting from global economic developments, geopolitical instability and conflicts. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

    ProQR Therapeutics N.V.

    Investor contact:

    Sarah Kiely

    ProQR Therapeutics N.V.

    T: +1 617 599 6228

    [email protected]

    or

    Peter Kelleher

    LifeSci Advisors

    T: +1 617 430 7579

    [email protected]

    Media contact:

    Robert Stanislaro

    FTI Consulting

    T: +1 212 850 5657

    [email protected]



    Primary Logo

    Get the next $PRQR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRQR

    DatePrice TargetRatingAnalyst
    4/29/2025$5.00Outperform
    Evercore ISI
    4/29/2025$8.00Overweight
    Cantor Fitzgerald
    3/10/2025$4.00Neutral → Buy
    Citigroup
    1/10/2025$15.00Outperform
    Oppenheimer
    10/29/2024$6.00 → $14.00Outperform → Strong Buy
    Raymond James
    11/8/2023$2.00Neutral → Buy
    Chardan Capital Markets
    3/30/2023$1.50 → $5.00Mkt Perform → Mkt Outperform
    JMP Securities
    12/22/2022$0.80 → $5.00Neutral → Overweight
    Cantor Fitzgerald
    More analyst ratings

    $PRQR
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by ProQR Therapeutics N.V.

    SCHEDULE 13G/A - ProQR Therapeutics N.V. (0001612940) (Subject)

    8/12/25 9:03:49 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by ProQR Therapeutics N.V.

    6-K - ProQR Therapeutics N.V. (0001612940) (Filer)

    8/7/25 7:00:15 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by ProQR Therapeutics N.V.

    6-K - ProQR Therapeutics N.V. (0001612940) (Filer)

    6/26/25 4:41:20 PM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRQR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI initiated coverage on ProQR Therapeutics with a new price target

    Evercore ISI initiated coverage of ProQR Therapeutics with a rating of Outperform and set a new price target of $5.00

    4/29/25 8:12:03 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald resumed coverage on ProQR Therapeutics with a new price target

    Cantor Fitzgerald resumed coverage of ProQR Therapeutics with a rating of Overweight and set a new price target of $8.00

    4/29/25 8:11:53 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProQR Therapeutics upgraded by Citigroup with a new price target

    Citigroup upgraded ProQR Therapeutics from Neutral to Buy and set a new price target of $4.00

    3/10/25 7:58:48 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRQR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ProQR Announces Second Quarter 2025 Operating and Financial Results

    Submitted CTA for lead program AX-0810, targeting NTCP for cholestatic diseasesAdvancing AX-2402 program toward clinical candidate selection, targeting MECP2 (R270X) for Rett SyndromeHosting fall Analyst and Investor Event (virtual), featuring detailed AX-0810 Phase 1 trial design and 2025 data expectations, plus updates across differentiated liver and CNS pipeline€ 119.8 million cash and cash equivalents as of end Q2 – providing runway into mid-2027, not including additional potential milestones from Lilly partnership LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) --  ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through tran

    8/7/25 7:00:00 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProQR Announces Upcoming Presentation at RNA Editing Summit

    LEIDEN, Netherlands & CAMBRIDGE, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will participate in the RNA Editing Summit taking place July 29-31, 2025, in Boston, MA. "We recently achieved a key milestone with the submission of the CTA for AX-0810, targeting NTCP for cholestatic diseases, and we're building on this momentum with continued progress in CNS applications of our Axiomer technology," said Gerard Platenburg, Chief Scientific Officer of ProQR. "Our presentation at the RNA Edit

    7/28/25 8:00:00 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

    First-in-human trial of AX-0810 will evaluate safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers with initial data expected in Q4 2025Marks the first submitted Clinical Trial Application (CTA) advancing ProQR's Axiomer™ ADAR-mediated RNA editing platform into clinical development LEIDEN, Netherlands & CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the submission of a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to initiate a

    6/26/25 4:30:00 PM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRQR
    Leadership Updates

    Live Leadership Updates

    View All

    ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth

    LEIDEN, Netherlands & CAMBRIDGE, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the appointment of Dennis Hom as Chief Financial Officer (CFO) and Cristina Lopez Lopez, MD, PhD, as Chief Medical Officer (CMO). These key leadership appointments support the advancement of the Company's Axiomer platform technology and pipeline of RNA editing programs as it enters the clinical stage. "We are thrilled to welcome Dennis and Cristina to ProQR at such an important time in our evolution," said Daniel A

    4/14/25 7:00:00 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the appointment of Dr. Peter Beal, a professor of Chemistry at the University of California, Davis, as Chief ADAR Scientist. Dr. Beal, one of the top experts in ADAR and RNA biology and chemistry, has been a long-term collaborator of ProQR and a valued member of ProQR's Scientific Advisory Board, where he has played an important role in shaping the Company's ADAR-based RNA editing platform. Dr. Beal's decades of res

    12/10/24 8:00:00 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProQR Appoints John Maraganore, PhD, as Strategic Advisor to the Supervisory Board

    LEIDEN, Netherlands & CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (the "Company"), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that John Maraganore, PhD, biopharma industry leader and the former founding CEO of Alnylam Pharmaceuticals, has joined ProQR as a strategic advisor.  "It is a great honor to have John engaged with ProQR as a strategic advisor to the Supervisory Board to support us in defining the next steps for the Company, while we continue to analyze data from the Illuminate trial of sepofarsen and identify next steps for the program, if any,"

    3/7/22 7:00:00 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRQR
    Financials

    Live finance-specific insights

    View All

    ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced that the Company will host a virtual Analyst and Investor Event on Wednesday, December 11, 2024 from 10:00 am until approximately 12:30 pm EST, including an Analyst Q&A session with members of the ProQR Management Team.  During the event, ProQR will highlight its proprietary Axiomer™ ADAR-mediated RNA editing platform, along with updates on its pipeline of development candidates including data updates and next steps on its programs for NTCP and B4GALT1, AX-0810 and AX-1412. Prese

    12/5/24 8:00:00 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases

    ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing OligonucleotidesPreclinical proof of concept for the Company's AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT Annual MeetingManagement webinar May 9, 2024 at 8:00 am EDT LEIDEN, Netherlands & CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced new preclinical data for its proprietary Axiomer™ RNA editing technology platform, incl

    5/8/24 8:00:00 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced that ProQR management will host an investor conference call and webcast to discuss the Company's Axiomer RNA editing technology platform following the recently announced partnership expansion with Lilly. ProQR will host the call on December 22, 2022, at 8:15am EST.  The live and archived webcast of the presentation will be accessible through this webcast link, or to access the live call by phone please register here. A dial-in and unique PIN will be provided to join the call. The

    12/22/22 6:15:00 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRQR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by ProQR Therapeutics N.V. (Amendment)

    SC 13G/A - ProQR Therapeutics N.V. (0001612940) (Subject)

    2/14/24 6:08:12 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by ProQR Therapeutics N.V. (Amendment)

    SC 13G/A - ProQR Therapeutics N.V. (0001612940) (Subject)

    2/9/24 6:37:13 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by ProQR Therapeutics N.V.

    SC 13G - ProQR Therapeutics N.V. (0001612940) (Subject)

    9/14/23 5:20:05 PM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care